Two Years On The Market And Only A 7% Volume Share – J&J Numbers Reveal Infliximab Struggle For US Biosimilars

 
• By Dean Rudge
  
PumpkinPie
Biosimilars sponsors in the US have only captured a small piece of the infliximab pie thus far. • Source: Shutterstock

More from Biosimilars

More from Products